-
With the commencement of GMP manufacturing operations, OrganaBio’s CDMO offers the cell therapy industry ready access to flexible manufacturing solutions and clinical grade cellular raw materials.
-
OrganaBio, a cell therapy CDMO, expands manufacturing with ISO 7 cleanrooms for 3rd party manufacturing and GMP cellular starting material production.
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
Defined Bioscience to Develop Stem Cells and iPSC-derived Tissue for Life Science and Cultivated Meat Applications
Defined Bioscience Announces Formation of Its Scientific Advisory Board
San Diego, CA, June 15, 2022 —Â Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Defined Bioscience team on the development and commercialization of cell culture reagents, growth medium and kits to consistently grow high quality stem cells and iPSC-derived tissue with applications in life science and cultivated meat. [Read more…]
A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously: To be presented at ISSCR 2022 Annual Meeting
Palo Alto, California, June 14, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously. There are various automated cell processing/expansion systems in the market today, but this is the first high-throughput, automated cell processing system that is capable of inducing iPSCs from somatic cells. [Read more…]
Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology
Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.
PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®
SALT LAKE CITY, May 13, 2022 –PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to SkinTE under the Company’s open IND. [Read more…]
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 146
- Next Page »